These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 24126613)

  • 1. Safety and tolerability of sublingual immunotherapy in clinical trials and real life.
    Senna G; Caminati M; Canonica GW
    Curr Opin Allergy Clin Immunol; 2013 Dec; 13(6):656-62. PubMed ID: 24126613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice.
    Bernstein DI; Bardelas JA; Svanholm Fogh B; Kaur A; Li Z; Nolte H
    Postgrad Med; 2017 Aug; 129(6):590-597. PubMed ID: 28326906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?
    Nelson HS
    J Allergy Clin Immunol Pract; 2014; 2(2):144-9; quiz 150-1. PubMed ID: 24607040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies.
    Calderon MA; Casale TB; Nelson HS; Demoly P
    J Allergy Clin Immunol; 2013 Dec; 132(6):1322-36. PubMed ID: 24139829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New administration routes for immunotherapy].
    Martorell Aragonés A
    Allergol Immunopathol (Madr); 2000; 28(3):93-102. PubMed ID: 10867377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures.
    Pham-Thi N; Scheinmann P; Fadel R; Combebias A; Andre C
    Pediatr Allergy Immunol; 2007 Feb; 18(1):47-57. PubMed ID: 17295799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis.
    Creticos PS; Esch RE; Couroux P; Gentile D; D'Angelo P; Whitlow B; Alexander M; Coyne TC
    J Allergy Clin Immunol; 2014 Mar; 133(3):751-8. PubMed ID: 24332263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New visions in specific immunotherapy in children: an iPAC summary and future trends.
    Halken S; Lau S; Valovirta E
    Pediatr Allergy Immunol; 2008 Aug; 19 Suppl 19():60-70. PubMed ID: 18665964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One century of allergen-specific immunotherapy for respiratory allergy.
    Incorvaia C; Frati F
    Immunotherapy; 2011 May; 3(5):629-35. PubMed ID: 21554092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Vaccination with allergens in children].
    Demoly P; Dhivert-Donnadieu H; Bousquet J
    Allerg Immunol (Paris); 2000 Dec; 32(10):397-401. PubMed ID: 11209473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A Meta-analysis of efficacy and safety of sublingual immunotherapy on allergic asthma].
    Wu YY; Xie XM; Han D; Li SJ; Liu L; Li MX
    Zhonghua Nei Ke Za Zhi; 2013 Oct; 52(10):844-8. PubMed ID: 24378062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma.
    Bahceciler NN; Cobanoglu N
    Immunotherapy; 2011 Jun; 3(6):747-56. PubMed ID: 21668312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives in the treatment of allergic rhinitis and asthma in children.
    Baena-Cagnani CE; Passalacqua G; Gómez M; Zernotti ME; Canonica GW
    Curr Opin Allergy Clin Immunol; 2007 Apr; 7(2):201-6. PubMed ID: 17351477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate adverse reactions to immunotherapy.
    Can D; Demir E; Tanaç R; Gülen F; Yenigün A
    J Investig Allergol Clin Immunol; 2003; 13(3):177-80. PubMed ID: 14635467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy: clinical trials--optimal trial and clinical outcomes.
    Bousquet PJ; Demoly P; Passalacqua G; Canonica GW; Bousquet J
    Curr Opin Allergy Clin Immunol; 2007 Dec; 7(6):561-6. PubMed ID: 17989535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sublingual immunotherapy in the treatment of adult allergic rhinitis patients.
    Canonica GW; Passalacqua G
    Allergy; 2006; 61 Suppl 81():20-3. PubMed ID: 16792602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of sublingual immunotherapy in Asian children.
    Park IH; Hong SM; Lee HM
    Int J Pediatr Otorhinolaryngol; 2012 Dec; 76(12):1761-6. PubMed ID: 22959336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
    Esch RE; Bush RK; Peden D; Lockey RF
    Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.